What's new — Depression¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 4 |
| last 2 months | 7 |
| last 3 months | 10 |
| last 6 months | 27 |
| last year | 43 |
| older than a year | 352 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-10-02 | Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial — JAMA ([PMID 42931733](https://pubmed.ncbi.nlm.nih.gov/42931733/){target="_blank" rel="noopener"}) | clinical-trials-landscape, psychedelics-and-novel-therapeutics |
| 2026-10-02 | Efficacy of Non-Invasive Brain Stimulation on the Treatment of Late Life Depression: A Systematic Review and Network Meta-Analysis — Acta Psychiatr Scand ([PMID 42924478](https://pubmed.ncbi.nlm.nih.gov/42924478/){target="_blank" rel="noopener"}) | neuromodulation |
| 2026-10-02 | Multimodal Machine Learning-Based Prediction of Relapse in Major Depressive Disorder — JAMA Psychiatry ([PMID 42905697](https://pubmed.ncbi.nlm.nih.gov/42905697/){target="_blank" rel="noopener"}) | biomarkers-and-treatment-prediction |
| 2026-10-02 | Copenhagen Magnetic Personalized Accelerated Brain Circuit Therapy (CoMPACT) trial: study protocol for a randomized, double-blinded, sham-controlled, three-armed, parallel-group trial of transcranial magnetic stimulation for treatment-resistant depression — Front Psychiatry ([PMID 42890690](https://pubmed.ncbi.nlm.nih.gov/42890690/){target="_blank" rel="noopener"}) | clinical-trials-landscape, neuromodulation |
| 2026-10-01 | Home Transcranial Direct Current Stimulation With Gamified Cognitive Control Training for Depression: A Randomized Clinical Trial — JAMA Netw Open ([PMID 42895746](https://pubmed.ncbi.nlm.nih.gov/42895746/){target="_blank" rel="noopener"}) | clinical-trials-landscape, neuromodulation |
| 2026-10-01 | Transcranial alternating current stimulation for major depressive disorder: An updated systematic review and meta-analysis of randomized trials with GRADE assessment — J Affect Disord ([PMID 42880603](https://pubmed.ncbi.nlm.nih.gov/42880603/){target="_blank" rel="noopener"}) | neuromodulation |
| 2026-09-05 | NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trials — Neuropsychopharmacology ([PMID 42701110](https://pubmed.ncbi.nlm.nih.gov/42701110/){target="_blank" rel="noopener"}) | ketamine-and-glutamatergic-agents |
| 2026-08-06 | Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial — Nat Med ([PMID 42562964](https://pubmed.ncbi.nlm.nih.gov/42562964/){target="_blank" rel="noopener"}) | psychedelics-and-novel-therapeutics |
| 2026-08-04 | Resting-state fMRI-based machine learning for predicting SSRI treatment response in major depressive disorder — BMC Psychiatry ([PMID 42552532](https://pubmed.ncbi.nlm.nih.gov/42552532/){target="_blank" rel="noopener"}) | biomarkers-and-treatment-prediction |
| 2026-08-02 | Dysregulated adult hippocampal neurogenesis in major depressive disorder — Nat Med ([PMID 42629468](https://pubmed.ncbi.nlm.nih.gov/42629468/){target="_blank" rel="noopener"}) | neurobiology-and-mechanisms |
| 2026-07-07 | Revisiting the Exercise Recommendations in the 2023 CANMAT Guidelines for Major Depressive Disorder — Can J Psychiatry ([PMID 42411994](https://pubmed.ncbi.nlm.nih.gov/42411994/){target="_blank" rel="noopener"}) | guidelines |
| 2026-07-03 | Reappraising lithium, triiodothyronine and second-generation antipsychotic augmentation treatment for major depression: a systematic review and meta-analysis with bias-adjustment analyses — BMJ Ment Health ([PMID 42532626](https://pubmed.ncbi.nlm.nih.gov/42532626/){target="_blank" rel="noopener"}) | treatment-resistant-depression |
| 2026-07-03 | Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis — Front Psychiatry ([PMID 42490943](https://pubmed.ncbi.nlm.nih.gov/42490943/){target="_blank" rel="noopener"}) | guidelines |
| 2026-07-03 | The use of patient-reported outcome measures in assessing the prevalence and tolerance of SSRI-related sexual dysfunction: a systematic review — J Sex Med ([PMID 42466890](https://pubmed.ncbi.nlm.nih.gov/42466890/){target="_blank" rel="noopener"}) | antidepressant-pharmacology |
| 2026-07-03 | Ketamine alters the aperiodic EEG exponent in major depression: implications for cortical E/I balance and treatment prediction — Ther Adv Psychopharmacol ([PMID 42403511](https://pubmed.ncbi.nlm.nih.gov/42403511/){target="_blank" rel="noopener"}) | biomarkers-and-treatment-prediction |
| 2026-07-02 | Transdiagnostic medication-associated weight gain across five effectiveness trials: a harmonized longitudinal cohort analysis of antipsychotics, antidepressants, and mood stabilizers — Prog Neuropsychopharmacol Biol Psychiatry ([PMID 42492718](https://pubmed.ncbi.nlm.nih.gov/42492718/){target="_blank" rel="noopener"}) | antidepressant-pharmacology |
| 2026-07-01 | [Inflammatory depression: a review of advances in pathophysiology, clinical implications, and treatment] — Rev Med Inst Mex Seguro Soc ([PMID 42447470](https://pubmed.ncbi.nlm.nih.gov/42447470/){target="_blank" rel="noopener"}) | biomarkers-and-treatment-prediction |
| 2026-07-01 | Post-SSRI Sexual Dysfunction (PSSD): A comprehensive review of epidemiology, pathophysiology, and clinical management — Int J Risk Saf Med ([PMID 42430418](https://pubmed.ncbi.nlm.nih.gov/42430418/){target="_blank" rel="noopener"}) | antidepressant-pharmacology |
| 2026-07-01 | Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder: A Systematic Review and Network Meta-Analysis — J Evid Based Med ([PMID 42383744](https://pubmed.ncbi.nlm.nih.gov/42383744/){target="_blank" rel="noopener"}) | neuromodulation |
| 2026-07-01 | Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode: A Systematic Review and Meta-Analysis — JAMA Psychiatry ([PMID 42090166](https://pubmed.ncbi.nlm.nih.gov/42090166/){target="_blank" rel="noopener"}) | clinical-trials-landscape, ketamine-and-glutamatergic-agents |
| 2026-07-01 | Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis — JAMA Psychiatry ([PMID 42090141](https://pubmed.ncbi.nlm.nih.gov/42090141/){target="_blank" rel="noopener"}) | guidelines |
| 2026-07-01 | Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review — JAMA Psychiatry ([PMID 41984443](https://pubmed.ncbi.nlm.nih.gov/41984443/){target="_blank" rel="noopener"}) | psychedelics-and-novel-therapeutics |
| 2026-06-06 | An umbrella review of inflammatory biomarkers and their relationship to treatment response in MDD — Neurosci Biobehav Rev ([PMID 42252042](https://pubmed.ncbi.nlm.nih.gov/42252042/){target="_blank" rel="noopener"}) | neurobiology-and-mechanisms |
| 2026-06-02 | Baseline inflammatory profiles in moderate-to-severe depression and differential response to intermittent theta-burst stimulation — Prog Neuropsychopharmacol Biol Psychiatry ([PMID 42364721](https://pubmed.ncbi.nlm.nih.gov/42364721/){target="_blank" rel="noopener"}) | biomarkers-and-treatment-prediction, neuromodulation |
| 2026-05-23 | Updated trends in the global prevalence and burden of mental disorders, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023 — Lancet ([PMID 42167272](https://pubmed.ncbi.nlm.nih.gov/42167272/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-05-09 | Diagnostic accuracy of machine learning approaches for suicide‑related outcomes: a meta‑analysis — Ann Gen Psychiatry ([PMID 42106827](https://pubmed.ncbi.nlm.nih.gov/42106827/){target="_blank" rel="noopener"}) | suicide-risk-and-mortality |
| 2026-05-04 | Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial — J Clin Psychiatry ([PMID 42095692](https://pubmed.ncbi.nlm.nih.gov/42095692/){target="_blank" rel="noopener"}) | ketamine-and-glutamatergic-agents, psychotherapy-and-combination |
| 2026-05-01 | Machine Learning for Comparative Antidepressant Selection in Major Depressive Disorder: Systematic Review — JMIR Ment Health ([PMID 42126586](https://pubmed.ncbi.nlm.nih.gov/42126586/){target="_blank" rel="noopener"}) | biomarkers-and-treatment-prediction |
| 2026-04-05 | Predictive neuroimaging biomarkers of major depressive disorder treatment response: An umbrella review — Psychiatry Clin Neurosci ([PMID 41935973](https://pubmed.ncbi.nlm.nih.gov/41935973/){target="_blank" rel="noopener"}) | biomarkers-and-treatment-prediction |
| 2026-03-06 | Assessing the presence of biasing and non-biasing unblinding in a randomized controlled trial of a home-use tDCS device: An exploratory analysis — J Affect Disord ([PMID 41796776](https://pubmed.ncbi.nlm.nih.gov/41796776/){target="_blank" rel="noopener"}) | clinical-trials-landscape, neuromodulation |
| 2026-03-03 | Effect of exercise on depression and anxiety symptoms: systematic umbrella review with meta-meta-analysis — Br J Sports Med ([PMID 41667154](https://pubmed.ncbi.nlm.nih.gov/41667154/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-02-01 | Combining xQTL and genome-wide association studies from diverse populations improves druggable gene discovery — Nat Commun ([PMID 41690969](https://pubmed.ncbi.nlm.nih.gov/41690969/){target="_blank" rel="noopener"}) | genetics |
| 2026-01-02 | Beyond first-line antidepressants: lithium, quetiapine, or esketamine? Integrating meta-analyses and preliminary head-to-head evidence — World J Biol Psychiatry ([PMID 41572784](https://pubmed.ncbi.nlm.nih.gov/41572784/){target="_blank" rel="noopener"}) | treatment-resistant-depression |
| 2026-01-01 | Comparison of antidepressant deprescribing strategies in individuals with clinically remitted depression: a systematic review and network meta-analysis — Lancet Psychiatry ([PMID 41386898](https://pubmed.ncbi.nlm.nih.gov/41386898/){target="_blank" rel="noopener"}) | psychotherapy-and-combination |
| 2025-12-02 | Cross-trial prediction of treatment response to transcranial direct current stimulation in patients with major depressive disorder — Prog Neuropsychopharmacol Biol Psychiatry ([PMID 41456664](https://pubmed.ncbi.nlm.nih.gov/41456664/){target="_blank" rel="noopener"}) | biomarkers-and-treatment-prediction |
| 2025-12-01 | Longitudinal associations of electroconvulsive therapy with all-cause mortality and suicide deaths in severe unipolar or bipolar depression: a systematic review and meta-analysis — BMJ Ment Health ([PMID 41407487](https://pubmed.ncbi.nlm.nih.gov/41407487/){target="_blank" rel="noopener"}) | neuromodulation, suicide-risk-and-mortality |
| 2025-12-01 | Mapping the genetic landscape across 14 psychiatric disorders — Nature ([PMID 41372416](https://pubmed.ncbi.nlm.nih.gov/41372416/){target="_blank" rel="noopener"}) | genetics |
| 2025-11-07 | Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis — Eur Neuropsychopharmacol ([PMID 41205366](https://pubmed.ncbi.nlm.nih.gov/41205366/){target="_blank" rel="noopener"}) | psychedelics-and-novel-therapeutics |
| 2025-11-04 | Effectiveness of Psychological Therapies for Depression During the Perinatal Period : A Systematic Review and Meta-analysis — Ann Intern Med ([PMID 41183344](https://pubmed.ncbi.nlm.nih.gov/41183344/){target="_blank" rel="noopener"}) | psychotherapy-and-combination |
| 2025-11-02 | Efficacy and safety of esketamine for "treatment resistant depression": registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials — BMC Med ([PMID 41310599](https://pubmed.ncbi.nlm.nih.gov/41310599/){target="_blank" rel="noopener"}) | the-efficacy-debate |
| 2025-11-01 | Association of endogenous hormones with major depressive disorder phenotype: A systematic review and meta-analysis of drug-free case and control cross-sectional study — Biochem Biophys Res Commun ([PMID 41270487](https://pubmed.ncbi.nlm.nih.gov/41270487/){target="_blank" rel="noopener"}) | neurobiology-and-mechanisms |
| 2025-11-01 | Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, Phase 3 clinical trial — Psychiatry Clin Neurosci ([PMID 41251319](https://pubmed.ncbi.nlm.nih.gov/41251319/){target="_blank" rel="noopener"}) | psychedelics-and-novel-therapeutics |
| 2025-11-01 | Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis — Ther Adv Psychopharmacol ([PMID 41244961](https://pubmed.ncbi.nlm.nih.gov/41244961/){target="_blank" rel="noopener"}) | clinical-trials-landscape, ketamine-and-glutamatergic-agents |
Trials — what has moved¶
31 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 3 |
| trial records updated in the last month | 6 |
| trial records updated in the last 2 months | 10 |
| trial records updated in the last 3 months | 15 |
| trial records updated in the last 6 months | 18 |
| trial records updated in the last year | 21 |
Recently updated registrations¶
| Updated | Trial | Phase | Status | N | Cited on |
|---|---|---|---|---|---|
| 2026-10-30 | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | PHASE3 | RECRUITING | 330 | clinical-trials-landscape, psychedelics-and-novel-therapeutics |
| 2026-10-28 | Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder | PHASE2 | RECRUITING | 230 | clinical-trials-landscape |
| 2026-10-27 | Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Inflixim | PHASE2 | RECRUITING | 100 | biomarkers-and-treatment-prediction, clinical-trials-landscape |
| 2026-10-19 | Transcranial Direct Current Stimulation for Depression | NA | RECRUITING | 25 | clinical-trials-landscape |
| 2026-10-19 | A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD | PHASE2 | COMPLETED | 126 | clinical-trials-landscape, psychedelics-and-novel-therapeutics |
| 2026-10-05 | Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutam | PHASE2 | RECRUITING | 50 | clinical-trials-landscape, ketamine-and-glutamatergic-agents, psychedelics-and-novel-therapeutics |
| 2026-09-22 | DBS for TRD With the Medtronic Percept PC | NA | RECRUITING | 20 | clinical-trials-landscape, neuromodulation |
| 2026-09-21 | Treating Immuno-metabolic Depression With Anti-inflammatory Drugs | PHASE3 | COMPLETED | 94 | clinical-trials-landscape |
| 2026-09-18 | Imaging- vs. Scalp-Targeted Accelerated TMS for Depression: The Number Needed to Scan Tria | NA | NOT_YET_RECRUITING | 160 | clinical-trials-landscape |
| 2026-09-10 | BPL-003 Efficacy and Safety in Treatment Resistant Depression | PHASE2 | COMPLETED | 196 | clinical-trials-landscape, psychedelics-and-novel-therapeutics |
| 2026-08-28 | Psilocybin in Depression Resistant to Standard Treatments | PHASE2 | COMPLETED | 60 | clinical-trials-landscape, psychedelics-and-novel-therapeutics |
| 2026-08-26 | COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant | NA | RECRUITING | 78 | clinical-trials-landscape, neuromodulation |
| 2026-08-20 | Home-Based Wearable rTMS Therapy for Moderate to Severe Depression | NA | NOT_YET_RECRUITING | 124 | clinical-trials-landscape, neuromodulation |
| 2026-08-03 | Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal | PHASE4 | NOT_YET_RECRUITING | 12 | ketamine-and-glutamatergic-agents |
| 2026-08-03 | Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | PHASE2 | RECRUITING | 164 | clinical-trials-landscape |
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | BPL-003 Efficacy and Safety in Treatment Resistant Depression | PHASE2 | 196 | Core: Change From Baseline in Montgomery and Asberg Depression Rating | 5 | 236 | 0 |
26 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| biomarkers-and-treatment-prediction | 2026-10-02 | 8 | 31 |
| clinical-trials-landscape | 2026-10-02 | 6 | 29 |
| neuromodulation | 2026-10-02 | 8 | 30 |
| psychedelics-and-novel-therapeutics | 2026-10-02 | 5 | 28 |
| ketamine-and-glutamatergic-agents | 2026-09-05 | 4 | 30 |
| neurobiology-and-mechanisms | 2026-08-02 | 3 | 33 |
| guidelines | 2026-07-07 | 3 | 34 |
| antidepressant-pharmacology | 2026-07-03 | 3 | 25 |
| treatment-resistant-depression | 2026-07-03 | 2 | 30 |
| epidemiology-and-burden | 2026-05-23 | 1 | 28 |
| suicide-risk-and-mortality | 2026-05-09 | 2 | 25 |
| psychotherapy-and-combination | 2026-05-04 | 3 | 27 |
| patient-experience-and-advocacy | 2026-03-03 | 1 | 25 |
| genetics | 2026-02-01 | 2 | 25 |
| the-efficacy-debate | 2025-11-02 | 1 | 27 |
| overview | 2025-10-01 | 0 | 32 |
| red-flags-and-safety-concerns | 2025-10-01 | 0 | 25 |
| diagnostic-criteria-and-heterogeneity | 2025-05-02 | 0 | 25 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.